JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

Smith & Nephew PLC ADR

Закрыт

30.89 1.68

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

30.35

Макс.

30.97

Ключевые показатели

By Trading Economics

Доход

35M

331M

Продажи

203M

3.2B

P/E

Средняя по отрасли

22.441

67.147

Дивидендная доходность

2.44

Рентабельность продаж

10.368

Сотрудники

16,988

EBITDA

133M

856M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+2.96% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

2.44%

2.36%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-1.5B

14B

Предыдущая цена открытия

29.21

Предыдущая цена закрытия

30.89

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Smith & Nephew PLC ADR График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

29 апр. 2026 г., 23:53 UTC

Отчет

Naver Posts Weaker First-Quarter Earnings

29 апр. 2026 г., 23:41 UTC

Популярные акции

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 апр. 2026 г., 23:55 UTC

Отчет

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 апр. 2026 г., 23:54 UTC

Отчет

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 апр. 2026 г., 23:52 UTC

Отчет

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 апр. 2026 г., 23:51 UTC

Отчет

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 апр. 2026 г., 23:51 UTC

Обсуждения рынка

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 апр. 2026 г., 23:34 UTC

Обсуждения рынка

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 апр. 2026 г., 23:24 UTC

Отчет

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 апр. 2026 г., 23:24 UTC

Отчет

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 апр. 2026 г., 23:24 UTC

Отчет

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 апр. 2026 г., 23:24 UTC

Отчет

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 апр. 2026 г., 23:22 UTC

Отчет

China Longyuan 1Q Net CNY1.70B, Down 14%

29 апр. 2026 г., 23:22 UTC

Отчет

China Longyuan: Power Generation Down 2.9% as of End-March

29 апр. 2026 г., 23:20 UTC

Отчет

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 апр. 2026 г., 23:20 UTC

Отчет

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 апр. 2026 г., 23:19 UTC

Отчет

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 апр. 2026 г., 23:19 UTC

Отчет

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 апр. 2026 г., 23:19 UTC

Отчет

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 апр. 2026 г., 23:19 UTC

Отчет

China Vanke 1Q Loss Narrows>000002.SZ

29 апр. 2026 г., 23:18 UTC

Отчет

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 апр. 2026 г., 23:17 UTC

Отчет

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 апр. 2026 г., 23:15 UTC

Отчет

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 апр. 2026 г., 23:15 UTC

Отчет

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 апр. 2026 г., 23:13 UTC

Отчет

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 апр. 2026 г., 23:12 UTC

Отчет

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 апр. 2026 г., 23:11 UTC

Отчет

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 апр. 2026 г., 23:11 UTC

Отчет

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 апр. 2026 г., 23:04 UTC

Отчет

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 апр. 2026 г., 23:04 UTC

Отчет

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Сравнение c конкурентами

Изменение цены

Smith & Nephew PLC ADR Прогноз

Целевая цена

By TipRanks

2.96% рост

Прогноз на 12 месяцев

Средняя 32 USD  2.96%

Максимум 32 USD

Минимум 32 USD

Основано на мнении 1 аналитиков Wall Street, спрогнозировавших целевые цены для Smith & Nephew PLC ADR на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

1 ratings

0

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

26.64 / 28.37Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

Bullish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat